Mankind Pharma has acquired the Indian rights to Rivotril, the long?established brand from Swiss giant Roche, to scale its presence in chronic and central nervous system (CNS) therapies, the New Delhi-based company said on March 18, without sharing the financial details for the deal.The deal grants Mankind exclusive rights to manufacture, market and distribute the drug in India, the compan...

Equity benchmarks extended their winning streak on September 18, with the Nifty closing above 25,400 for the first time since July 9, but the market breadth was slightly weak. About 1,436 shares saw selling pressure compared to 1,340 rising shares on the NSE. The market may see some consolidation, but overall, the mood remains bullish. Below are some short-term trading ideas to consider:Jay Mehta,...

The benchmark indices nosedived on February 3, with the Nifty 50 declining 0.5 percent. The market breadth was also in favor of the bears, as a total of 1,931 shares were under pressure against 649 shares that advanced on the NSE. As long as the market defends the midline of Bollinger Bands, the trend may remain in favor of bulls despite Monday's profit booking. Below are some trading ideas for th...

Shares of Mankind Pharma plunged nearly 6 percent on January 24, weighed down by a fall in the company's October-December net profit. The company's bottom line dropped over 16 percent on year in Q3 to Rs 385 crore, dented by a sharp rise in expenses.The drugmaker's Q3 net profit was also impacted by the $1.6 billion acquisition of Bharat Serums and Vaccines (BSV), which came into effect in October...

Shares of Mankind Pharma slipped 4 percent to Rs 2,606, snapping its two-day gaining streak on the bourses on January 21 after Macquarie downgraded Mankind Pharma to "Underperform" with a target price of Rs 2,150, reflecting a 7 percent downside from the previous close.The international brokerage said that the domestic formulations business remains weak, driven by slower growth in acute therapies,...